drugset / Trial / NCT03654664

To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine

NCT03654664

Phase 3 Completed 119 enrolled Boryung Pharmaceutical Co., Ltd
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to evaluate the immunogenicity and safety after one primary dose and one additional dose of inactivated hepatitis A vaccine are administered in Korean healthy children aged 12-23 months.

Timeline

Start
2017-06-20
Primary completion
2019-06-24
Completion
2019-06-24

Drugs

EvaluationDrugModalityDoseRoute
Comparator Havrix Inj Vaccine 0.5 ml
Subject Inactivated hepatitis A vaccine Vaccine 0.5 ml